Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.

Kopecky-Bromberg SA, Fraser KA, Pica N, Carnero E, Moran TM, Franck RW, Tsuji M, Palese P.

Vaccine. 2009 Jun 8;27(28):3766-74. doi: 10.1016/j.vaccine.2009.03.090. Epub 2009 Apr 23.

2.

Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.

Fotouhi F, Shaffifar M, Farahmand B, Shirian S, Saeidi M, Tabarraei A, Gorji A, Ghaemi A.

Arch Virol. 2017 May;162(5):1251-1260. doi: 10.1007/s00705-017-3230-7. Epub 2017 Jan 24.

PMID:
28120096
3.

Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.

Hung JT, Tsai YC, Lin WD, Jan JT, Lin KH, Huang JR, Cheng JY, Chen MW, Wong CH, Yu AL.

Antiviral Res. 2014 Jul;107:110-8. doi: 10.1016/j.antiviral.2014.04.007. Epub 2014 Apr 29.

PMID:
24786174
4.

An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.

Lee YS, Lee KA, Lee JY, Kang MH, Song YC, Baek DJ, Kim S, Kang CY.

Vaccine. 2011 Jan 10;29(3):417-25. doi: 10.1016/j.vaccine.2010.11.005. Epub 2010 Nov 16.

PMID:
21087689
5.

α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice.

Li K, Luo J, Wang C, He H.

Vaccine. 2011 Oct 13;29(44):7711-7. doi: 10.1016/j.vaccine.2011.07.136. Epub 2011 Aug 10.

PMID:
21839133
6.

An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.

Khalil SM, Tonkin DR, Snead AT, Parks GD, Johnston RE, White LJ.

J Virol. 2014 Aug;88(16):9182-96. doi: 10.1128/JVI.00327-14. Epub 2014 Jun 4.

7.
8.

Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs.

Dwivedi V, Manickam C, Dhakal S, Binjawadagi B, Ouyang K, Hiremath J, Khatri M, Hague JG, Lee CW, Renukaradhya GJ.

Vet Microbiol. 2016 Apr 15;186:157-63. doi: 10.1016/j.vetmic.2016.02.028. Epub 2016 Mar 2.

PMID:
27016770
9.

Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge.

Wang X, Zhang W, Liu F, Zheng M, Zheng D, Zhang T, Yi Y, Ding Y, Luo J, Dai C, Wang H, Sun B, Chen Z.

Arch Virol. 2012 Aug;157(8):1451-61. doi: 10.1007/s00705-012-1318-7. Epub 2012 May 4.

PMID:
22552485
10.

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.

Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, Gurner D, Gardiner D, Basu S, Ho DD, Tsuji M.

Vaccine. 2008 Mar 28;26(15):1807-16. doi: 10.1016/j.vaccine.2008.02.002. Epub 2008 Feb 20.

PMID:
18329757
11.

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.

Youn HJ, Ko SY, Lee KA, Ko HJ, Lee YS, Fujihashi K, Boyaka PN, Kim SH, Horimoto T, Kweon MN, Kang CY.

Vaccine. 2007 Jul 9;25(28):5189-98. Epub 2007 May 21.

PMID:
17548137
12.

Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.

van de Sandt CE, Kreijtz JH, Geelhoed-Mieras MM, Vogelzang-van Trierum SE, Nieuwkoop NJ, van de Vijver DA, Fouchier RA, Osterhaus AD, Morein B, Rimmelzwaan GF.

Vaccine. 2014 Sep 29;32(43):5614-23. doi: 10.1016/j.vaccine.2014.08.003. Epub 2014 Aug 17.

PMID:
25140929
13.
14.

Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.

Chua BY, Wong CY, Mifsud EJ, Edenborough KM, Sekiya T, Tan AC, Mercuri F, Rockman S, Chen W, Turner SJ, Doherty PC, Kelso A, Brown LE, Jackson DC.

MBio. 2015 Oct 27;6(6):e01024-15. doi: 10.1128/mBio.01024-15.

15.

Heightened adaptive immune responses following vaccination with a temperature-sensitive, live-attenuated influenza virus compared to adjuvanted, whole-inactivated virus in pigs.

Loving CL, Vincent AL, Pena L, Perez DR.

Vaccine. 2012 Aug 31;30(40):5830-8. doi: 10.1016/j.vaccine.2012.07.033. Epub 2012 Jul 24.

16.

A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

Hessel A, Schwendinger M, Fritz D, Coulibaly S, Holzer GW, Sabarth N, Kistner O, Wodal W, Kerschbaum A, Savidis-Dacho H, Crowe BA, Kreil TR, Barrett PN, Falkner FG.

PLoS One. 2010 Aug 16;5(8):e12217. doi: 10.1371/journal.pone.0012217.

17.

A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.

Dabaghian M, Latifi AM, Tebianian M, Dabaghian F, Ebrahimi SM.

Antiviral Res. 2015 Aug;120:23-31. doi: 10.1016/j.antiviral.2015.05.002. Epub 2015 May 16.

PMID:
25989418
18.

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.

Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M.

J Exp Med. 2002 Mar 4;195(5):617-24.

19.

Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, Brühl P, Gerencer M, Crowe BA, Shuo S, Hong W, Tan YJ, Dietrich B, Sabarth N, Savidis-Dacho H, Kistner O, Barrett PN, Falkner FG.

J Virol. 2009 May;83(10):5192-203. doi: 10.1128/JVI.02081-08. Epub 2009 Mar 11.

20.

Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.

Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa H, Seino KI.

Mucosal Immunol. 2008 May;1(3):208-18. doi: 10.1038/mi.2008.2. Epub 2008 Mar 5.

PMID:
19079180

Supplemental Content

Support Center